[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI1503756T1 - Epotilonski derivat za zdravljenje hepatoma in drugih rakavih bolezni - Google Patents

Epotilonski derivat za zdravljenje hepatoma in drugih rakavih bolezni

Info

Publication number
SI1503756T1
SI1503756T1 SI200331688T SI200331688T SI1503756T1 SI 1503756 T1 SI1503756 T1 SI 1503756T1 SI 200331688 T SI200331688 T SI 200331688T SI 200331688 T SI200331688 T SI 200331688T SI 1503756 T1 SI1503756 T1 SI 1503756T1
Authority
SI
Slovenia
Prior art keywords
treatment
progressing
cancer
radiotherapy
hepatoma
Prior art date
Application number
SI200331688T
Other languages
English (en)
Inventor
John David Rothermel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI1503756T1 publication Critical patent/SI1503756T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silicon Polymers (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SI200331688T 2002-05-01 2003-04-30 Epotilonski derivat za zdravljenje hepatoma in drugih rakavih bolezni SI1503756T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37706302P 2002-05-01 2002-05-01
PCT/EP2003/004581 WO2003092683A1 (en) 2002-05-01 2003-04-30 Epothilone derivative for the treatment of hepatoma and other cancer diseases
EP03725129A EP1503756B1 (en) 2002-05-01 2003-04-30 Epothilone derivative for the treatment of hepatoma and other cancer diseases

Publications (1)

Publication Number Publication Date
SI1503756T1 true SI1503756T1 (sl) 2010-01-29

Family

ID=29401440

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331688T SI1503756T1 (sl) 2002-05-01 2003-04-30 Epotilonski derivat za zdravljenje hepatoma in drugih rakavih bolezni

Country Status (24)

Country Link
US (2) US20050282873A1 (sl)
EP (1) EP1503756B1 (sl)
JP (1) JP2005528414A (sl)
KR (1) KR20040106422A (sl)
CN (1) CN1649585A (sl)
AT (1) ATE439130T1 (sl)
AU (1) AU2003227702B2 (sl)
BR (1) BR0309711A (sl)
CA (1) CA2483826C (sl)
CY (1) CY1109607T1 (sl)
DE (1) DE60328772D1 (sl)
DK (1) DK1503756T3 (sl)
ES (1) ES2330324T3 (sl)
HK (1) HK1073601A1 (sl)
IL (1) IL164783A (sl)
MX (1) MXPA04010853A (sl)
NO (1) NO20045249L (sl)
NZ (1) NZ536178A (sl)
PL (1) PL211114B1 (sl)
PT (1) PT1503756E (sl)
RU (1) RU2358730C2 (sl)
SI (1) SI1503756T1 (sl)
WO (1) WO2003092683A1 (sl)
ZA (1) ZA200408492B (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0309711A (pt) * 2002-05-01 2005-02-09 Novartis Ag Método para o tratamento de doenças do câncer
US20060235059A1 (en) * 2003-09-02 2006-10-19 Dilea Clifford Cancer treatment with epothilones
US8394365B2 (en) * 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
CA2597647A1 (en) 2005-02-11 2007-08-02 University Of Southern California Method of expressing proteins with disulfide bridges
US8008256B2 (en) 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
MX2008004268A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 24 horas.
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
CN101747326B (zh) * 2010-01-12 2012-07-25 山东大学 18元大环内酯类埃博霉素化合物及其应用
MX2012013100A (es) 2010-05-18 2013-01-22 Cerulean Pharma Inc Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
BR0008379A (pt) * 1999-02-22 2002-09-24 Biotechnolog Forschung Gmbh Epotilonas modificadas em c-21
GB9918429D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
BR0309711A (pt) * 2002-05-01 2005-02-09 Novartis Ag Método para o tratamento de doenças do câncer

Also Published As

Publication number Publication date
RU2358730C2 (ru) 2009-06-20
US20080161369A1 (en) 2008-07-03
PL371727A1 (en) 2005-06-27
PT1503756E (pt) 2009-10-28
NO20045249L (no) 2005-01-26
CN1649585A (zh) 2005-08-03
ES2330324T3 (es) 2009-12-09
RU2004135307A (ru) 2005-09-10
NZ536178A (en) 2007-10-26
HK1073601A1 (en) 2005-10-14
ATE439130T1 (de) 2009-08-15
EP1503756B1 (en) 2009-08-12
US20050282873A1 (en) 2005-12-22
ZA200408492B (en) 2006-09-27
AU2003227702B2 (en) 2007-07-26
DE60328772D1 (de) 2009-09-24
JP2005528414A (ja) 2005-09-22
CA2483826A1 (en) 2003-11-13
MXPA04010853A (es) 2005-02-14
CY1109607T1 (el) 2014-08-13
BR0309711A (pt) 2005-02-09
IL164783A0 (en) 2005-12-18
WO2003092683A1 (en) 2003-11-13
DK1503756T3 (da) 2009-11-16
KR20040106422A (ko) 2004-12-17
EP1503756A1 (en) 2005-02-09
IL164783A (en) 2011-08-31
PL211114B1 (pl) 2012-04-30
AU2003227702A1 (en) 2003-11-17
CA2483826C (en) 2012-04-17

Similar Documents

Publication Publication Date Title
CY1109607T1 (el) Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
SG170809A1 (en) Diarylthiohydantoin compounds
RU2012140185A (ru) Ингибирование ангиогенеза
RU2014108042A (ru) Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
PH12019502586A1 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
EA201201154A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
NZ597545A (en) Peptide epoxyketones for proteasome inhibition
RU2008150250A (ru) Способ лечения рака
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
DE602005015304D1 (de) Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer
ATE461713T1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
TW200724158A (en) Combination therapy in the treatment of cancer
WO2006031756A3 (en) Betulinol derivatives as anti-cancer agents
ATE400268T1 (de) Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen
ATE406375T1 (de) Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate
DK1572715T3 (da) Steroidforbindelser med antitumor-aktivitet
WO2005048956A3 (en) Estradiol-related compounds and methods of use as anti-tumor agents
TN2009000427A1 (en) Use of hdac inhibitors for the treatment of gastrointestinal cancers
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей